![logo](/logos/ATXS.webp)
Astria Therapeutics, Inc.
NASDAQ:ATXS
11.12 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Astria Therapeutics, Inc. |
Symbool | ATXS |
Munteenheid | USD |
Prijs | 11.12 |
Beurswaarde | 627,449,336 |
Dividendpercentage | 0% |
52-weken bereik | 4.26 - 16.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Jill C. Milne Ph.D. |
Website | https://www.astriatx.com |
An error occurred while fetching data.
Over Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)